Alnylam Pharmaceuticals (ALNY) Stock Price, Quote & News

Company Profile

Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 551 8200

Fax: 617 551 8101

Website: www.alnylam.com

Address:

675 West Kendall Street, Henri A. Termeer Square, Cambridge, United States

HedgeAlerts Dec. 4 at 7:16 AM

Hedge Alert Live - Protect Your Portfolio Contract: $ALNY $470.00 Put · DEC 19, 2025 Exp Entry Price: $13.20 - $17.30 Exit Price Target: $21.52 Profit Margin: +63% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

Quantumup Dec. 3 at 1:13 PM

H.C. Wainwright⬆️ $ARWR's PT to $85 from $80 and reiterated at a Buy rating. $IONS $REGN $ALNY $NVS Here's what H.C. Wainwright had to say in its note to investors: https://x.com/Quantumup1/status/1996204804981313869?s=20

0 · Reply

judgeyoung2 Dec. 3 at 4:38 AM

$CRH $VRT $ALNY $ARES candidates for SPX inclusion

0 · Reply

Arcides Dec. 2 at 7:05 PM

$ALNY a lot of bios are pupu today, not this one. Low volume

0 · Reply

HedgeAlerts Dec. 1 at 10:10 PM

Hedge Alert Live - Protect Your Portfolio Contract: $ALNY $450.00 Put · DEC 19, 2025 Exp Entry Price: $14.30 - $17.90 Exit Price Target: $32.75 Profit Margin: +129% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

johnnygogogo Dec. 1 at 9:46 PM

$ALNY S&P 500 index committee meeting to discuss new candidates cc: @skeezbag

0 · Reply

StageAnalysis Dec. 1 at 4:50 PM

$ALNY regaining its 50 day MA in Stage 2

0 · Reply

BillionerOfKing Dec. 1 at 2:40 PM

$ALNY Current Stock Price: $451.18 Contracts to trade: $450 ALNY Dec 19 2025 Call Entry: $17.82 Exit: $32.69 ROI: 83% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

SuperGreenToday Nov. 28 at 7:56 AM

$ALNY Share Price: $445.27 Contract Selected: Jun 18, 2026 $450 Calls Buy Zone: $64.00 – $79.06 Target Zone: $116.84 – $142.81 Potential Upside: 72% ROI Time to Expiration: 202 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

xbibackto1milly Nov. 26 at 4:39 PM

$ARWR maybe $ALNY is buying this? would make sense

0 · Reply

Alnylam Pharmaceuticals Announces Changes to Board of Directors

Dec 1, 2025, 3:47 PM EST - 3 days ago

CRH, Vertiv, Ares, Alnylam Could Be Added to S&P 500 Friday in Rebalancing

CRH VRT ARCC

Nov 30, 2025, 9:23 AM EST - 5 days ago

American Century Ultra Fund Q3 2025 Contributors/Detractors And Notable Trades

CMG FICO GOOG LULU MSFT NFLX ORCL

Nov 28, 2025, 12:42 PM EST - 6 days ago

What's Going On With Alnylam Stock On Friday?

Nov 26, 2025, 1:38 PM EST - 8 days ago

Virtus Silvant Mid-Cap Growth Fund Q3 2025 Performance Review

AFRM AJG ALAB AXON DXCM FICO HOOD

Nov 20, 2025, 7:09 PM EST - 14 days ago

UK's drug-cost watchdog recommends Alnylam's heart disease drug

Nov 19, 2025, 8:33 AM EST - 16 days ago

Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 11, 2025, 5:40 AM EST - 24 days ago

Got $5,000? 3 Top Growth Stocks to Buy That Could Double Your Money

IONQ TOST

Nov 10, 2025, 12:41 PM EST - 24 days ago

Alnylam Pharmaceuticals, Inc. (ALNY) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 8, 2025, 4:57 PM EST - 26 days ago

New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM

Nov 5, 2025, 8:10 AM EST - 4 weeks ago

American Century Focused Dynamic Growth Fund Q3 2025 Performance Contributors And Detractors

AAPL APP CMG GOOGL INSM NFLX STZ

Nov 4, 2025, 8:00 AM EST - 4 weeks ago

Alnylam to Webcast Presentations at Upcoming November Investor Conferences

Nov 3, 2025, 9:58 AM EST - 4 weeks ago

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

ABBV AMGN BMY LLY MBX MDGL MEDI

Oct 31, 2025, 3:58 PM EDT - 4 weeks ago

Alnylam Pharmaceuticals: Q3 Earnings Review - A Sensational Year Reaches Its Peak

Oct 30, 2025, 2:46 PM EDT - 5 weeks ago

Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 2:39 PM EDT - 5 weeks ago

Why Is Alnylam Pharmaceuticals Stock Trading Lower Thursday?

Oct 30, 2025, 8:00 AM EDT - 5 weeks ago

Alnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress

Oct 16, 2025, 8:00 AM EDT - 7 weeks ago

Alnylam to Webcast Conference Call Discussing Third Quarter 2025 Financial Results

Oct 1, 2025, 7:30 AM EDT - 2 months ago

Alnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran

Sep 28, 2025, 11:13 AM EDT - 2 months ago

New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran

Sep 23, 2025, 2:23 PM EDT - 2 months ago

Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum Transcript

Sep 18, 2025, 9:15 AM EDT - 2 months ago

Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine

ILMN

Sep 10, 2025, 5:01 PM EDT - 3 months ago

Alnylam Pharmaceuticals, Inc. (ALNY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 9, 2025, 11:16 PM EDT - 3 months ago

Alnylam Announces Pricing of Upsized Offering of $575 Million Convertible Senior Notes

Sep 8, 2025, 4:15 PM EDT - 3 months ago

Alnylam Announces Proposed Offering of $500 Million Convertible Senior Notes

Sep 3, 2025, 4:58 PM EDT - 3 months ago

Alnylam Pharmaceuticals, Inc. (ALNY) Presents At Citi's Biopharma Back To School Conference Prepared Remarks Transcript

Sep 3, 2025, 12:56 AM EDT - 3 months ago

Alnylam Pharmaceuticals: Amvuttra's Launch And Ongoing Clinical Progress Are Positives

Aug 31, 2025, 5:15 AM EDT - 3 months ago

New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran's Long-Term Cardiovascular Benefit in ATTR-CM

Aug 30, 2025, 10:30 AM EDT - 3 months ago

Genentech and Alnylam Advance Zilebesiran Into Global Phase III Cardiovascular Outcomes Trial for People With Uncontrolled Hypertension

Aug 30, 2025, 10:30 AM EDT - 3 months ago

Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial

Aug 28, 2025, 6:20 AM EDT - 3 months ago

mRNA Biotechs - Long-Term Value Risks Abound

BNTX DHR GRAL ILMN IONS MRNA RGEN

Aug 27, 2025, 8:00 AM EDT - 3 months ago

Alnylam to Webcast Presentations at Upcoming September Investor Conferences

Aug 26, 2025, 5:00 AM EDT - 3 months ago

Scenic Enters License and Research Agreement with Alnylam

Aug 11, 2025, 8:00 AM EDT - 4 months ago

Alnylam to Present Progress in Transforming the Treatment of Cardiovascular Disease with RNAi Therapeutics at European Society of Cardiology Congress 2025

Aug 5, 2025, 8:00 AM EDT - 4 months ago

Alnylam to Webcast Presentation at Canaccord Genuity 45th Annual Growth Conference

Aug 1, 2025, 2:28 PM EDT - 4 months ago

Alnylam's Amvuttra Makes Powerful Entrance, Eyes First-Line Dominance

Aug 1, 2025, 8:31 AM EDT - 4 months ago

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

ABBV ABT AMGN ARGX AZN BAX BIIB

Aug 1, 2025, 6:54 AM EDT - 4 months ago

President Trump demands drugmakers slash prices within 60 days

ABBV ABT AMGN ARGX AZN BAX BIIB

Jul 31, 2025, 4:47 PM EDT - 4 months ago

Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 3:36 PM EDT - 4 months ago

Alnylam Pharmaceuticals Q2 Earnings Crush Estimates, Stock Hits 52-Week High On Upbeat Forecast

Jul 31, 2025, 3:13 PM EDT - 4 months ago

Alnylam: Amvuttra Is Just Getting Started

Jul 31, 2025, 8:00 AM EDT - 4 months ago

Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress

Jul 23, 2025, 9:57 AM EDT - 4 months ago

Five years after COVID, pharma shares languish in US policy limbo

ABBV ABT AZN EW LLY MRK NVO

Jul 17, 2025, 8:00 AM EDT - 5 months ago

Alnylam to Webcast Conference Call Discussing Second Quarter 2025 Financial Results

Jul 1, 2025, 9:06 AM EDT - 5 months ago

Alnylam Pharma Stock Outlook: Is ALNY Topping Out?

Jun 18, 2025, 12:04 PM EDT - 6 months ago

Alnylam Pharmaceuticals Names Garg R&D Chief

Jun 18, 2025, 10:05 AM EDT - 6 months ago

Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development Officer

Jun 9, 2025, 6:00 AM EDT - 6 months ago

Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy

May 28, 2025, 8:00 AM EDT - 6 months ago

Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference

May 24, 2025, 6:40 AM EDT - 6 months ago

3 High-Flying Stocks That Could Soar Even More

AXSM SMMT

HedgeAlerts Dec. 4 at 7:16 AM

0 · Reply

Quantumup Dec. 3 at 1:13 PM

0 · Reply

judgeyoung2 Dec. 3 at 4:38 AM

$CRH $VRT $ALNY $ARES candidates for SPX inclusion

0 · Reply

Arcides Dec. 2 at 7:05 PM

$ALNY a lot of bios are pupu today, not this one. Low volume

0 · Reply

HedgeAlerts Dec. 1 at 10:10 PM

0 · Reply

johnnygogogo Dec. 1 at 9:46 PM

$ALNY S&P 500 index committee meeting to discuss new candidates cc: @skeezbag

0 · Reply

StageAnalysis Dec. 1 at 4:50 PM

$ALNY regaining its 50 day MA in Stage 2

0 · Reply

BillionerOfKing Dec. 1 at 2:40 PM

0 · Reply

SuperGreenToday Nov. 28 at 7:56 AM

0 · Reply

xbibackto1milly Nov. 26 at 4:39 PM

$ARWR maybe $ALNY is buying this? would make sense

0 · Reply

Quantumup Nov. 26 at 12:22 PM

Cantor reit'd $VERA Overweight-$100/said—We continue to view VERA shares as undervalued ($1.8B mkt cap with $497M cash as of Sep 30), given the competitive profile in lgAN, a multi-$B market that can easily accommodate multiple disease-modifying B cell modulators. $OTSKY $JBIO $ALNY $ABBV VRTX NVS IONS Cantor additionally said: This view is in line with that of multiple investors we spoke to at ASN who believe IgAN is a >$10B market for B-cell modulators. Our math suggests IgAN patients with proteinuria ≥0.5 g/day (76% according to literature (here)) represent 85K-151K US patients. Assuming annualized Tarpeyo pricing (~$180K), this subgroup alone could represent a market opportunity >$15B.

0 · Reply

HedgeAlerts Nov. 26 at 2:25 AM

Hedge Alert Live - Protect Your Portfolio Contract: $ALNY $420.00 Put · DEC 19, 2025 Exp Entry Price: $13.60 - $14.90 Exit Price Target: $25.30 Profit Margin: +86% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

HedgeAlerts Nov. 25 at 2:26 AM

Hedge Alert Live - Protect Your Portfolio Contract: $ALNY $430.00 Put · DEC 19, 2025 Exp Entry Price: $15.40 - $19.30 Exit Price Target: $33.57 Profit Margin: +118% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

SuperGreenToday Nov. 24 at 9:40 PM

$ALNY Share Price: $434.31 Contract Selected: Jun 18, 2026 $430 Calls Buy Zone: $51.42 – $63.53 Target Zone: $86.66 – $105.92 Potential Upside: 59% ROI Time to Expiration: 205 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

johnnygogogo Nov. 24 at 6:24 PM

$ARWR Daniel Day Anzalone to $ALNY and $IONS (this GIF is too good to leave buried in another thread).

1 · Reply

ElliottwaveForecast Nov. 23 at 12:51 PM

📊 $ALNY Pullback can Reach $390 Alnylam larger degree pullback taking place within a 3 swings structure and looking for equal legs area $390 - $342 before buyers show up again. 🔗 Full analysis: https://elliottwave-forecast.com/stock-market/alnylam-alny-extending-rally-final-stage/ #Biotech #Stocks #ElliottWave

0 · Reply

HedgeAlerts Nov. 23 at 3:48 AM

Hedge Alert Live - Protect Your Portfolio Contract: $ALNY $430.00 Put · DEC 19, 2025 Exp Entry Price: $16.90 - $18.20 Exit Price Target: $35.66 Profit Margin: +111% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

HedgeAlerts Nov. 21 at 11:11 PM

0 · Reply

mikeg1999 Nov. 21 at 9:01 PM

$CRSP right now is like $ALNY back in 2016. if successful, in 2036 CRSP could have a $50-100B market cap, no cap

0 · Reply

johnnygogogo Nov. 21 at 7:10 PM

$ALNY the Palantir of bios / pharma. That sucking sound you hear today isn’t champagne slurps but rather the index factors changing on a Friday, exactly one month out from quarterly rebalance, quietly and begrudgingly recognizing that Alnylam isn’t a monopoly on commercial standalone RNAi companies anymore. Welcome to the party $ARWR @skeezbag @BikeRieder @LeftyT @Pantherfan7979 @simonsp

3 · Reply

HedgeAlerts Nov. 20 at 11:22 PM

Hedge Alert Live - Protect Your Portfolio Contract: $ALNY $440.00 Put · DEC 19, 2025 Exp Entry Price: $18.50 - $19.20 Exit Price Target: $31.45 Profit Margin: +70% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

PaulY123 Nov. 20 at 1:46 PM

Shared this on Yahoo! but those people are a bunch of yahoos. I welcome thoughts on this from people who know the business of $ALNY Something is up with ALNY. The stock has been remarkably resilient during this market dip. Too early to pre-announce new guidance, even though all signs point to Amvuttra gaining massive traction (scripts are ramping fast). They will be due very large payments from Roche for milestones met with Zilebesiran. I know Regeneron has been generating great data for Cemdisiran for a few different indications (GA, IgAN, PNH, gMG, etc.). Lots of M&A going on in biotech/pharma this year, but ALNY would be a pretty big target. I do love the idea of Regeneron and Alnylam Pharmaceuticals combining via merger - especially with the approval of Eylea HD last evening. Anyone have insight or thoughts about this situation (this question is for intellectually advanced people only who actually understand this company and the biopharma landscape)?

1 · Reply

Market Cap	61.42B
Revenue (ttm)	2.25B
Net Income (ttm)	-278.16M
EPS (ttm)	N/A
PE Ratio	2,021.43
Forward PE	252.89
Profit Margin	-12.37%
Debt to Equity Ratio	0.00

Volume	983,900
Avg Vol	1,056,726
Day's Range	N/A - N/A
Shares Out	132.11M
Stochastic %K	89%
Beta	0.30
Analysts	Strong Sell
Price Target	$501.52